T-Cell Activation Method Patent

EPO published Takeda Pharmaceutical Company and Noile-Immune Biotech's patent application EP4321534A1 for a method of activating T-cells. The patent covers immunotherapy technology using antibody-based approaches (C07K 16/28) combined with cellular processing methods (C12N 5/0783). The inventors are Ogaki, Araki, and Maeda. The patent designates 34 European states including Germany, France, UK, Italy, Spain, and other EU/EEA members.

Pharmaceutical companies, biotech firms, and research institutions engaged in T-cell immunotherapy development should review this publication for freedom-to-operate considerations. Competitors developing similar T-cell activation technologies may need to evaluate potential licensing requirements or design-around options. This publication does not impose compliance deadlines or regulatory requirements but represents a significant intellectual property position in the cellular therapy space.